Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community‐based cohort study

• Published in: Journal of gastroenterology and hepatology Vol. 36; no. 11; pp. 3239 - 3246
• Main Authors: Yeh, Ming‐Lun, Liang, Po‐Cheng, Huang, Ching‐I, Hsieh, Meng‐Hsuan, Lin, Yi‐Hung, Jang, Tyng‐Yuan, Wei, Yu‐Ju, Hsu, Po‐Yao, Hsu, Cheng‐Ting, Wang, Chih‐Wen, Hsieh, Ming‐Yen, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Huang, Chung‐Feng, Huang, Jee‐Fu, Dai, Chia‐Yen, Chuang, Wan‐Long, Yu, Ming‐Lung
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.11.2021
• Subjects: Antigens; Anti‐HBs; Cohort analysis; Confidence intervals; HBsAg; HBV; Hepatitis B; Hepatitis B - immunology; Hepatitis B - therapy; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis C; Humans; Immunosuppressive agents; Incidence; Infections; Retrospective Studies; Seroreversion; Viruses; Seroreversion; HBsAg; HBV; Anti-HBs; Incidence
• ISSN: 0815-9319; 1440-1746; 1440-1746
• DOI: 10.1111/jgh.15640

Background and Aim Hepatitis B virus (HBV) surface antigen (HBsAg) seroreversion usually occurs during immunosuppressive therapy. The risk and factors of HBsAg seroreversion from resolved HBV infection in the general population remained unclear. Methods This retrospective study enrolled subjects with resolved HBV infection and who had received at least two times of screening in a longitudinal community screening program. HBsAg, hepatitis B surface antibody (anti‐HBs), and hepatitis C virus antibody (anti‐HCV) were tested every time in all subjects. The primary endpoint was HBsAg seroreversion. Results Of the 7630 subjects enrolled, 5158 (67.6%) subjects had positive anti‐HBs at baseline. HBsAg seroreversion occurred in 84 subjects during 42 815‐person‐year follow‐up with an annual incidence of 0.2% and a 10‐year cumulative risk of 1.9%. Anti‐HBV treatment‐experienced subjects had a significantly higher risk of HBsAg seroreversion than anti‐HBV treatment‐naive subjects (83/310 [26.8%] vs 1/7320 [0.01%], P < 0.001). Lower rates of positive anti‐HBs and anti‐HCV were observed in anti‐HBV treatment‐experienced subjects who developed HBsAg seroreversion. Both positive anti‐HBs (hazard ratio/95% confidence interval: 0.56/0.348–0.903, P = 0.017) and positive anti‐HCV (hazard ratio/95% confidence interval: 0.08/0.030–0.234, P < 0.001) were independent factors of HBsAg seroreversion in anti‐HBV treatment‐experienced subjects. Less than 5% of the HBsAg seroreverters had clinical hepatitis flare at HBsAg seroreversion. The HBsAg titer was low, and only transient reappeared in most of the HBsAg seroreverters. Conclusions Subjects with resolved HBV infection were at a minimal risk of HBsAg seroreversion, unless with prior anti‐HBV treatment experience. Fortunately, even with a reappearance of HBsAg, it was transient and clinically non‐relevant.